Table 3.

Relationships between oxidative damage at the TP53 level and the mutational spectrum of the TP53 in malignant breast tumours

Codon number	Site of DNA lesione	RI ± s.e.a	Ratiob	Nomenclature	Tumour distribution (%)	Mutational event	Mutational rateb (%)
163	(-TAC-)	0.19 ± 0.02	1.27	c.487T>A	0.28	A:T→T:A	6.57
170	(-ACG-)	0.51 ± 0.04	1.7	c.511G>A	0.03	G:C→A:T	20.68
173	(-GTG-)	0.44 ± 0.05	1.57	c.517G>T	0.31	G:C→T:A	10.58
175	(-CGC-)	0.23 ± 0.03	1.27 at CpG	c.524G>A	4.52	G:C→A:T at CpG	18.37

^aThe mean levels of oxidative lesions, expressed as relative intensity (RI), in breast cancer patients.

^bRatio = levels of oxidative damage at the TP53 sequence levels in breast cancer cases/levels of oxidative DNA damage of controls.

^cPrevalence of mutations at the site of DNA lesions at the TP53 sequence level.

^dPrevalence of transversion and transition mutations in the TP53.

^eUnderlined letters indicate the residues for which oxidative lesions are reported.